Practical Implementation of TG 263's Standardized Nomenclatures Across Multiple Radiation Oncology Practices



Carnell Hampton, PhD, DABR

Nomenclature and Big Data – TG 263 and the Future 2019 AAPM Spring Clincal Meeting March 2019 At the conclusion of this presentation, the participant will be able to:

- Describe Task Group 263's goals and recommendations
- Review clinical examples and receive guidance for gaining efficiencies across multiple software platforms used during the radiation therapy process across a multi-facility practice
- Explore the use of metrics designed to quantify efficiency gains realized by implementing the Task Group's recommendations



Disclosures

• None

Date of the Party

WHERE A

This Photo by Unknown Author is licensed under CC BY-SA


B N N N N N N

1.1.1.1.1.1.1.1




- Why Standardize?
- Challenges in a multifacility community-based practice
- Case Study: Standardized Clinical Treatment Planning Standards
 - SBRT Lung

















LCI Rad Therapy By the Numbers:

9 physical locations

6 single-linac facilities & 3 multiplelinac sites

350+ patients daily

> 2000 special procedures annually

Multisite American College of Radiology (ACR) Accreditation

AAPM Task Group 263

- Report issued in 2017
- 57 stakeholders
 - Physicists, Physicians, Dosimetrists, Members of Cooperative group trials, AAPM, DICOM working group, ASTRO, IHE-RO
- Develop consensus position on nomenclature for use in clinical trials, datapooling initiatives, populations-based studies and routine clinical care by standardizing:
 - Structure names across platforms
 - Nomenclature for dosimetric data
 - Templates for clinical trials groups and users
 - Formalism for nomenclature schema for the future

International Journal of Radiation Oncology biology • physics

www.redjournal.or

CrossMark

Critical Review

American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology

Charles S. Mayo, PhD,* Jean M. Moran, PhD,* Walter Bosch, PhD,† Ying Xiao, PhD,[‡] Todd McNutt, PhD,[§] Richard Popple, PhD,[®] Jeff Michalski, MD,[†] Mary Feng, MD,[¶] Lawrence B. Marks, MD, PhD,[#] Clifton D. Fuller, MD, PhD,** Ellen Yorke, PhD,^{††} Jatinder Palta, PhD,^{‡‡} Peter E. Gabriel, MD,[‡] Andrea Molineu, MS,** Martha M. Matuszak, PhD,* Elizabeth Covington, PhD, Kathryn Masi, PhD,⁵⁸ Susan L. Richardson, PhD,¹¹¹ Timothy Ritter, PhD,^{##} Tomasz Morgas, *** Stella Flampouri, PhD, T Lakshmi Santanam, PhD, Joseph A. Moore, PhD,[§] Thomas G. Purdie, PhD,^{‡‡} Robert C. Miller, MD, 555 Coen Hurkmans, PhD, Judy Adams, MS, ### Qing-Rong Jackie Wu, PhD, **** Colleen J. Fox, PhD, Ramon Alfredo Siochi, PhD,¹¹¹¹ Norman L. Brown, HScD,⁸⁶⁸⁸ Wilko Verbakel, PhD, Yves Archambault, MS,*** Steven J. Chmura, #### Andre L. Dekker, ***** Don G. Eagle, MS, ***** Thomas J. Fitzgerald, MD,¹¹¹¹¹ Theodore Hong, MD,¹¹¹ Rishabh Kapoor, MS,^{‡‡} Beth Lansing,^{§§§§§} Shruti Jolly, MD,* Mary E. Napolitano, PhD, James Percy, SSSSS Mark S. Rose, MS, Salim Siddigui, MD, ##### Christof Schadt, ****** William E. Simon, MS, ##### William L. Straube, Sara T. St. James, PhD,¹¹¹¹¹¹ Kenneth Ulin, PhD,¹ Sue S. Yom, MD, PhD,[¶] and Torunn I. Yock, MD, MCH^{###}

*University of Michigan, Ann Arbor, Michigan; ¹Washington University, St. Louis, Missouri; ¹University of Pennsylvania, Philadelphia, Pennsylvania; ¹Johns Hopkins University, Baltimore,

Reprint requests to: Charles S. Mayo, PhD, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109. Tel: (734) 232-3837; E-mail: cmayo@med.umich.edu Conflict of interest: Dr Molineu reports grants from the National conduct of the study. Dr Bosch reports grants from the US National Institutes of Health, during the conduct of the study. Supplementary material for this article can be found at www.redjournal.org.

Why Standardize?

- Clarity in communication among team members
 - Are we talking about the same things?
 - Is our INTENT clear?
 - Are we using AMBIGUOUS methods of communicating?

 Table 1. Variations in standardized nomenclatures reported for non-target structures by 16 institutions.

 The number in () indicates the number of respondents using the same value if > 1.

| Structure | Number of Institutions | Examples | | |
|-----------------------------|---------------------------|--|--|--|
| Left Optic Nerve | 12 | Lt Optic Nerve, OPTICN_L, OPTNRV_L, optic_nrv_l, L_optic_nerve, OPTIC_NRV_L, OpticNerve_L, LOPTIC, OpticNerve_L (3), Lef Optic Nerve, ON_L | | |
| Left Lung | 12 | Lt Lung, Lung_L(4), LUNG_L(3), lung_I, L_lung, LLUNG, L Lung | | |
| Both Lungs | 12 | Lungs(2), LUNGs, LUNG_TOTAL, lung_total, combined_lung, LUNG, LUNGS(2), Lung,BilatLung, Lung_Both | | |
| 8th Cranial Nerve | 7 | CN_VIII(5), cn_viii(2), CN8, CN_8 | | |
| Right External Iliac Artery | 2 | A_ILIAC_E_R, a_iliac_e_r | | |

Why Standardize?

| Clarity in communication among systems | CT Scanners EMRs Treatment Delivery systems Image management systems |
|--|---|
| | |
| Sometimes OUr systems don't cooperate | Character limits Case sensitivity Incompatible characters ^, *, #, ' |

A kick in the pants...

Multisite ACR re-accreditation in 2016

ACR-ASTRO Practice Guidelines

- Define the goals and requirements of the treatment plan, including the specific dose constraints for the target(s) and nearby critical structure(s).
- Delineate tumor and specify and approve target volumes, preferably using appropriate methodology of the International Commission on Radiation Units and Measurements (ICRU).
- Review and approve all critical structures contoured. Perform final evaluation and approve the final IMRT plan for implementation
- Additional recommendation to specify goals and "close the loop" by recording results of planning process
- This was an opportunity...

- Automation
- Solution needed to be deployable across multiple sites
- Configuration allowed for standardization to be encouraged/enforced

| Constraint Template | | LCI LungSBRT - 50Gy in 5fx Prescriptions | | | | | | | | Constraints DVH Structure Check | |
|------------------------|----------|--|-------------------|--------|--------------------|--|--------------|-----------|-----------|---------------------------------------|-----------------|
| LCI_LungSBRT | | | | | Prescr | iption Total Dose | | | | | 🗸 Margin Checks |
| | | | | | Lung | SBRT 6000 | | | | | Plan Checks |
| an Check Template | | | | | | | | | | | |
| | | | | | LCI LungSBRT - | 50Gy in 5fx Constraints | | | | | |
| leport Template | | Structure | Charles | | | | | | | | 1 |
| Aria Report IMRT_SBR Y | Priority | Template | Structure Plan | Туре | Prescription | Constraint | Goal | Left Lung | Pass/Fail | Comment | |
| | 1 | PTV | PTV01 | Target | | V5000cGy ≥ | 95% | 100% | ~ | | |
| | 2 | PTV | PTV01 | Target | Lung SBRT: 6000cGy | D99% ≥ | 90% | 97.293% | 1 | | |
| c2 | 3 | PTV | PTV01 | Target | Lung SBRT: 6000cGy | Max ≤ | 160% | 115.517% | 1 | | |
| an | 4 | PTV | PTV01 | Target | Lung SBRT: 6000cGy | (RTOG Homogeneity Index) RHI 100% \leq | 1.11-1.67 | 1.155 | Δ | | |
| Left Lung 🗸 | 5 | PTV | PTV01 | Target | Lung SBRT: 6000cGy | (V105% < PTV15%) Dose Spill V105% \leq | 15% | 0.262% | ~ | | |
| | 6 | PTV | PTV01 | Target | Lung SBRT: 6000cGy | (Conformality Index) CI 100% \leq | 1.2-1.5 | 0.994 | ~ | | |
| ose eft Lung | 7 | PTV | PTV01 | Target | Lung SBRT: 6000cGy | (R50%) CI 50% ≤ | 4.127-5.127 | 4.761 | Δ | | |
| 1200cGy x 5 = 6000cGy | 8 | ITV | ITV | Target | | V5000cGy ≥ | 100% | 100% | ~ | | |
| | 9 | Body-PTV+2cm | Body-PTV+2 | OAR | Lung SBRT: 6000cGy | (D2cm) MaxDT using PTV01 volume ≤ | 60.3-73.175% | 73.846% | × | JH | |
| Report | 10 | Spinal Cord | SpinalCord | OAR | | V2200cGy ≤ | 0.35cc | Occ | ~ | | |
| | 11 | Spinal Cord | SpinalCord | OAR | | D0.035cc ≤ | 2800cGy | 1017.8cGy | ~ | | |

ClearCheck

- ClearCheck is a script that is integrated into the Eclipse treatment planning software that provides plan quality assurance functionality
- Made optimally efficient through the matching of planning structures and a template
- TG-263 Standardized nomenclature can easily be incorporated into templates



| | ***** | -1, | · · · · · | e Net Anne Pythone Petrology Anne | nda Anata Sala Anata | 10 De La Santa - Jy D an her her for the Santa - Jy D to Mark - Santa - Jy D | |
|--|--|-----|-----------|--|--|--|--|
| | A provide the second se | | | Alternational and a second sec | Ame The second sec | | |



- Principles for non-target, target nomenclature
- Recommendations for DVH Metrics
- Implementation
- Nomenclature spreadsheet
 - >700 structure names
- Eclipse structure templates

TG-263 Resources

https://www.aapm.org/pubs/re ports/RPT_263_Supplemental/ Will my dosimetrists, physicists and oncologists EMBRACE standardization?



https://www.google.com/url?sa=i&source=images&cd=&cad=rja&uact=8&ved=2ahUKEwjzrrHO85XhAhWLTd8KHaDLAz0QjB16BAgBEAQ&url=https%3A%2F%2Fw ww.winshuttle.com%2Fblog%2Fshared-services-process-standardization%2F&psig=AOvVaw1UI4gjhho9fcTy1-J8vci5&ust=1553345806268298



Environmental Challenges

Regional practices

Varied environments

Lean staffing Vs Academic practice

Rotating Coverage

LCI LungSBRT -

Pres

Lund

Technology Challenges LungSBRT - 5

tructure Structure Type Prescription Multiple vendor environment emplate PTV 95% • 3 different EMRs – Varian ARIA 15.1, Varian Lung SBRT: 6000cGy PTV D99% ≥ 90% ARIA 13.6, Mosaiq • 3 different TPS – Varian Eclipse 15.1, Varian PTV 160% (RTOG Homogeneity -1.67PTV Eclipse 13.6, Raysearch Raystation PTV Lung SBRT: 6000cGy (V105%<PTV1 • 2nd Check Software – Radcalc Lung SBRT: 6000cGy PTV DVH & Objective Analysis Software – Lung SBRT: 6000cGy PTV ClearCheck ITV Target Image Management Database – MIM Maestro /-PTV+2cm (D2cn inal Cord SpinalCord OAR inal Cord SpinalCord OAR

Develop Implementation Plan


- Define goal
 - Realize efficiencies in the planning and plan documentation processes
 - Enhance safety by standardizing nomenclature
 - Demonstrate utilization and compliance with standards in all clinics
- Leading measure
 - Feedback/participation in weekly implementation meetings

Communication

- Communicate with all stakeholders the broad goal of standardization
- Provide documentation

Camplines Heat

LCI Radiation C Continuous Q Assurance Com




- Provide training
- Selectively introduce at robust clinical site
- Identify champions
- Develop best practices for workflows, protocols
- Gather feedback from smaller groups

Pilot Implementations

Expansion

- Introduce templates, workflows, protocols at a second rad therapy clinic
- Promote champion's experience
- Incorporate key lessons learned



Feedback

- Understand small process differences from clinic to clinic
- Identify roadbacks to implementation
- Perform necessary revisions
- Allow constrained creativity

| | | Max Do | se | | сGу | |
|--------------------------------|------------------|------------|--|-----------------------|--|---|
| | | Total Num | ber of | | | |
| | | Beam | ITV Dimensions PTV Volume | 6.1 | mm R _{50%} cc V _{Rx leodose/} V _{PTV} | 5.2 1.2 |
| | | Tota | PTV Dimensions Total Rx Dose | 5400 cGy | mm D _{2cm} Max Daily Daily | Dose 2630 cGy |
| Radiotherapy Prescription | | | # of fractions | 3 | PTV Rx isodose Coverage | e (V _{Rx}) 95.0 % |
| | | | V _{50%RxExternal} V _{Rx} isodoseExternal | 27.9 cc 6.8 cc | Max D _{99%} D _{95%} | |
| Dose per Fraction Total Dose | 18 6 | iy x 3 5 | V 105%Non-target tissue | , <mark>0.6</mark> cc | D ₁₀₀ | @ ^{2cm*} 2174 cGy ‰ITV <u>6427</u> cGy ≿ Dose 40 % |
| Implementation | | e close t | V _{Rx i800089} ÷ V _{PTV} V _{50%Rx} Iso ÷ V _{PTV} D _{max} @ 2cm (% of Rx Dose) V _{105%} ≤ PTV _{15%} | 4.6 Compliant | $\begin{array}{l} D_{95\%} PTV \geq 90\% \ Rx \ Isodose? \\ D_{55\%} PTV \geq Rx \ Isodose? \\ D_{100\%} ITV \geq Rx \ Isodose? \end{array}$ | Compliant Compliant Compliant |
| of Standardized | /olume Receiving | Dose | Comments | | | |
| Organ | Tolerance (cc) |) To | lerance | | fx) | |
| spinal & Planning | 0 | ĉ | Goal | | 1590 | |
| -Standards. | 530 | | | | 2250 | |
| Ips. Brachial Plexus | | • | Impleme | ent Clear | Check as co | nsistent |
| LUNgmSBR (CGy) | | | quality g | soal attaii | Check as co ; OAR and ta nment | aiget platt |
| Lung (Right and Left) Volume: | 4557 | | | | of consisten | |
| ∨ 1080 | 315 | | nomenc | lature for | r all treatme | ent plans |
| | 4242 | • | Eliminat | e use of r | multiple spi | readsheets |
| ∨ 1140 | 303 | | | al plan so | coring shee | ts |
| Lanza Davashi | 7% | | <37% | | 1140 | |
| Large Bronchi | | | <5cc | | 3900 | |
| Maximum Dose (cGy) | | | | | 4300 | |
| Heart | 0 | | < 15cc | | 2400 | |

Practical Radiation Oncology (2019) 9, 65-72




Special Article

Standardizing Normal Tissue Contouring for Radiation Therapy Treatment Planning: An ASTRO Consensus Paper

Jean L. Wright MD^a, Sue S. Yom MD, PhD, MAS^b, Musaddiq J. Awan MD^c, Samantha Dawes CMD^d,*, Benjamin Fischer-Valuck MD^e, Randi Kudner MA^d, `aymond Mailhot Vega MD, MPH^f, George Rodrigues MD, PhD^g

⁴opkins University, Baltimore, Maryland; ^bUniversity of California, San Francisco, Calif ⁱⁿ, Milwaukee, Wisconsin; ^dAmerican Society for Radiation Oncology, Arlington, V ⁱⁿ; ^fUniversity of Florida, Jacksonville, Florida; ⁸London Health Science

revised 29 November 2018; accepted 8 December 2018



wention for tissue labels in this table align with American Association of Physicists in Medicine Task Group. Nomenclasse et in Radiation Oncology; [5]

| | Thoracic | |
|-----------------------|--------------|------------------------|
| Treated Organ | Recommended | Consider |
| | Heart | A_LAD |
| | Lung_L/R | BrachialPlex_L/R |
| Breast/Chestwall | | Breast (contralateral) |
| breasty chestwow | | Lungs |
| | | Ribs |
| | | Ventricle_L |
| | Lung_L/R | BrachialPlex_L/R |
| Supraclavicular Fossa | SpinalCord | Esophagus |
| 300100011000110330 | | Gin d_Thyroid |
| | | Lungs |
| | Heart | BrachialPlex_L/R |
| Axila | Lung_L/R | Esophagus |
| Carlle | SpinalCord | Gin d_Thyroid |
| | | Lungs |
| | Esophagus | A_LAD |
| | Heart | BrachialPlex_L/R |
| | Lung_L/R | Bronchus_L/R |
| | Lungs | Bronchus_Main |
| Lung | SpinalCord | Chest wall_L/R |
| | | Great Ves |
| | | Liver |
| | | Stomach |
| | | Trachea |
| | Esophagus | A_LAD |
| | Heart | Bronchus_Main |
| Mediasti num/Th ymus | Lung_L/R | Trachea |
| | Lungs | |
| | SpinalCord | |
| | Esophagus | Kid ney_L/R |
| | Heart | Kidneys |
| | Lung_L/R | Larynx |
| | Lungs | Liver |
| | Spin al Cord | |
| | Stomach | |

Methods

Create Standard for all LCI Clinics

- Download Eclipse template from TG-263 resource page, Import into Eclipse V15.1 and customize:
 - Inclusive of ASTRO consensus OARs
 - Consensus of names for planning structures
 - TG suggested target nomenclature
- Export configured Eclipse Structure Template and import into Eclipse V13.6

Filter

Global Templates

| | Tanadata | Anthur | |
|---|---------------------------|---|---|
| | Template | Active | |
| # | LCI LungSBRT - 50Gy in 5f | ✓ | - |
| Ħ | LCI LungSBRT - 54Gy in 3f | \checkmark | |
| Ħ | LCI_LungSBRT - 50Gy in 41 | ~ | |
| Ħ | LCI_HA-WBRT | Image: A set of the set of the | |
| Ħ | LCI_Prostate-Hypo | ~ | |
| H | LCI_Prostate-SBRT | ~ | |
| I | LCI_Prostate-Standard | ~ | |
| H | Default 3D | ~ | |
| I | Breast 3D | ~ | |
| Ħ | Whole Brain | ~ | |
| I | Breast e- Boost | ~ | |
| Ħ | Lung SBRT - 50Gy in 5fx | | |
| Ħ | Lung SBRT - 50Gy in 4fx | | |
| I | Lung SBRT - 54Gy in 3fx | | |
| | Total Prostate 79Gy | ~ | |
| : | Boost Prostate 28.8Gy | ~ | |
| I | Prostate/SV 45Gy | ~ | |
| I | Boost Prostate 34.2Gy | ~ | |
| I | Total Prostate 79.2Gy | ~ | |
| I | RTOG 0631 Spine | ~ | |
| Ħ | H&N 70Gy | | |
| H | H&N - 3 dose levels RH | ~ | |

+ \bigcirc \bigcirc \bigcirc \bigcirc \bigcirc

LCI LungSBRT - 50Gy in 5fx Prescriptions

Prescription Total Dose

Lung SBRT 5000

| τı | |
|----|--|

H


LCI LungSBRT - 50Gy in 5fx Constraints

| | Priority | Structure | Aliases | Туре | Prescription | | Constraint Type | Constraint | Сог |
|-----|----------|-----------------|--------------------------|----------|--------------------------|--------------|------------------------------|--|--------------------------------|
| I | 1 | PTV | PTV_5000, PTV01 | Target ~ | · | Vo | vilume v | V5000cGy>95% | |
| # | 2 | PTV | PTV_5000, PTV01 | Target ~ | Lung SBRT: 5000cGy | * Do | ose 🗸 | D99%>90% | |
| Ħ | 3 | PTV | PTV_5000, PTV01 | Target ~ | Lung SBRT: 5000cGy | • M | хе хе | Max<160% | |
| Ħ | 4 | PTV | PTV_5000, PTV01 | Target 🗸 | Lung SBRT: 5000cGy | ~ RT | OG HI v | RHI100% | RTO G Hon Index |
| Ħ | 5 | PTV | PTV_5000, PTV01 | Target ~ | Lung SBRT: 5000cGy | Y Do | ose Spill | nfigure | V105% <p1< td=""></p1<> |
| Ħ | 6 | PTV | PTV_5000, PTV01 | Target ~ | Lung SBRT: 5000cGy | ~ CI | | | Conformal |
| Ħ | 7 | PTV | PTV_5000, PTV01 | Target ~ | Lung SBRT: 5000cGy | ~ CI | | arCheck | R50% |
| # | 8 | ITV | ITV | Target ~ | · | | | | |
| Ħ | 9 | Body-PTV+2cm | Body-PTV+2cm | OAR ~ | Lung SBRT: 5000cGy | ~ M | | nplates | D2cm |
| H | 10 | Spinal Cord | SpinalCord, Cord | OAR ~ | • | Vo | lume ICI | | |
| : | 11 | Spinal Cord | SpinalCord, Cord | OAR ~ | • | | ose 🗸 | D0.035cc<2800cGy | |
| I | 12 | SpinalCanal | SpinalCanal | OAR ~ | · | Use | TG-263 star | ndardized nomen | clature |
| : | 13 | SpinalCanal | SpinalCanal | OAR ~ | • | Do | exactly | <pre>/ matching TPS</pre> | |
| : | 14 | Brachial_Plex_R | Brachial_Plex_R, Rt | OAR 🗸 | , | Do | ^{se} No ně | ed for aliases! | |
| + [| Ì 🗇 | Structure Check | Cemplate LCI_LungSBRT | v Notes: | | | ave reviewed each specified | metric. Goals not achieved are noted in re | |
| | | Plan Check 1 | emplate | ~ | meaningful in this case. | s nom my pre | -specified goals are accepta | ble and appropriate in order to prioritize o | other goals tel t to be |
| | | Report | Template Aria Report IMR | T_ * | | | | | |

Process Refinement

- 3-week "trial" implementation
- All sites encouraged to use clinically
- Record feedback in worksheet
- Weekly Skype meetings with users to demonstrate functionality, answer questions and review feedback

| Standardized Nomenclature Feedback Tool Please provide feedback about items missing from either the Eclipse Template or ClearCheck | | | | | | | |
|--|---|---|---|--|--|--|--|
| | Please provide feedback about items missing from | m either the Eclipse Template or ClearCheck | | | | | |
| Product | Comment | User - Please Enter Name | Addressed; pericardium has same constraints | | | | |
| ClearCheck | Please add the Spinal Canal, small airway, Pericardium | | as heart. Changed cc name from "heart" to "heart/pericard" | | | | |
| Eclipse Template | Can PTVs be changed to translucent or contour? Our physicians do not like segment when looking at targets on CBCT | Romeo Boulet | Addressed; changed targets to translucent | | | | |
| ClearCheck SBRT Lung | The margin check is not in the print report template for SBRT lung. It is also not configured, standard is a 5 mm PTV expansion from the ITV. | Mark DiMascio | Addressed; added margin check for ITV->PTV expansion and added to report template | | | | |
| ClearCheck | What should be done about constraints objectives that are not met | | MDs should initial constraints that are unment during plan review. Standard language added to all cc templates. | | | | |
| ClearCheck | Better explaination for plan quality metrics | Ben Moeller/Ryan Foster | familiar nomenclature added as comments in template which print on final pdf | | | | |
| ClearCheck | It may be beneficial to add a rib contour to the template and constraints; we reference RTOG and Timmerman rib guidelines when annlicable | Nina Bahar | added Rib V3000cGy<30cc | | | | |
| ClearCheck | It may be beneficial to add a rib contour to the template and constraints; we reference RTOG and Timmerman rib | Nina Bahar | added Rib V3000cGy<30cc | | | | |
| | | | | | | | |



Results: Efficiency Metric

| | Description | Standardized Plan/Template | Manually Matched OAR Names | Manually Recorded from Eclipse DVH |
|-----------------------------------|-------------|-------------------------------|----------------------------------|--|
| Case #1 – SBRT (New User) | | 1 min 2 secs | 1 min 53 sec | N/A |
| Case #1 – SBRT (Experienced User) | 23 PTV/OAR | 0.32 secs | 0.43 sec | 5min 55 sec |
| Case #2 - IMRT Brain (new user) | 11 PTV/OAR | N/A | 1 min 3 secs | 2min 12 secs |
| Case #1 – IMRT Brain (exp. user) | IIII WOAK | N/A | 1 min | 1min 45 secs |

Results: Structure Naming Variation

LCI Before Standardization


- Lung_Lt, Lung L
- Aorta, large vessels, Great Vessels
- Bronchus_LT
- Small Airway, proximal bronch
- Spinal Cord, cord
- Total Lung
- Skin, Skin_dvh
- Brachial plexus
- Chest wall, chestwall

LCI After TG-263 Standardization

- Lung_L
- GreatVes
- Bronchus_Main
- AirWay_Prox
- SpinalCord
- Lungs, Lungs-ITV
- Skin
- BrachialPlex
- Chestwall

Results: Technique Adoption

- 4 of 9 practices deliver SBRT
- 100% utilization rate for ClearCheck matching to templates with standardized OAR nomenclature



Extension to Other Software Platforms

TG-263 Standardized Nomenclature

| RadCalc - Piedmont Carolir | | | | |
|--|-----------------------|-----------|---|---------|
| <u>F</u> ile <u>W</u> indow <u>H</u> elp | | | | |
| Piedmont Carolinas Radiation Therapy 💌 | eogin/Logout Previous | Next Open | - | -Do |
| titution Setup - Regions of Inter | rest Options | | _ | |
| Add ROIs from patient files | | | | |

gions of Interest Defaults

| ROI Name | Density | Visible by default | Do not import | Pseudonyms |
|---------------|---------|--------------------|---------------|----------------|
| AirWay_Prox | 0.500 | ✓ | | |
| Bones | 1.200 | ✓ | | |
| Chestwall | 1.000 | ✓ | ✓ | |
| CouchInterior | 0.250 | ✓ | | CouchInterior1 |
| CouchSurface | 0.700 | ✓ | | CouchSurface1 |
| Esophagus | 0.500 | ✓ | | |
| GreatVes | 1.000 | ✓ | ✓ | |
| Heart | 1.000 | ✓ | ✓ | |
| Liver | 1.000 | ✓ | ✓ | |
| Lung_L | 0.250 | ✓ | | |
| Lung_R | 0.250 | ✓ | | |
| - CTV | | - | | |

| ternal Regio | ternal Regions of Interest Defaults | | | | | | | | | | |
|--------------|-------------------------------------|--------------------|---------------|------------|--|--|--|--|--|--|--|
| | | | | | | | | | | | |
| ROI Name | Density | Visible by default | Do not import | Pseudonyms | | | | | | | |
| BODY | 1.000 | ✓ | | EXTERNAL | | | | | | | |

Use External defined by planning system, if presen

Use Planning System External over External ROI List, if both are presen

Use External ROI List over Planning System External, if both are present


If density is specified in the plan, use it instead of ROI Preset

Automatic Density Assignments

- Radcalc ROI module recognizes and matches imported structures names matching the TG-263 standardized OAR names in the configuration utility
- Default densities, visibility for structures can be set
- No need for pseudonyms

MIM Maestro

- MIM Maestro custom workflows configured to load "SBRT Lung" ROI templates using TG-263 standardized ROI nomenclature
- Deployment of MIM at all Rad. Therapy centers promotes standardization across platforms



RapidPlan

Standardized nomenclature simplifies the matching of structures to the RapidPlan template

| A | dd Plan COURSE1 / Pelvis BST | to DVH Estima | tion Model - Wing | o, Haywood (17250) | | | | |
|---------------|------------------------------|---------------|-------------------|-------------------------------------|---------------------|--|------------|---|
| ## 2.0 cn | | Model ID | | | | | | 2 |
| ning) Brachyt | | Prostate | e - UC San Diego | p Pelv | s Thurs | day, March 28, 2019 | 1:50:49 PM | • |
| Unapproved - | Model Version | 40.0.00 | | | | | | - CT_Pelvis |
| •] | | Pelvis | | | | | | € ^H X |
| | Trained Published | | | | | | | \$1 c |
| | | | than (JROGER2 | 3) Thursday, March 28, 2019 | 1:50:49 PM | | | |
| | | | blished 11-04-2 | 016 (kevinmoore@ucsd.edu), Marie | Cornell CMD (mcorr | ell@uced.edu) | | and the second |
| | | | gebasedrt.org | Kevininoore@ucsu.edu), mane | Conten, CIMD (Incon | ien@dcsd.edd) | | |
| | | Clinical Desc | cription | | | | | |
| | | | | | | | | 101.7 |
| | | 3240.0 | cGy | | | | | A second s |
| | Plan Structure ID (C | Codes) | Туре | Model Structure ID (Codes) | Target Dose | | | |
| 7.0.00 - | Bladder (15900) | | ORGAN | BLADDER (15900) | | Femur_L, | Femur_R | E F |
| Unapproved - | Bladder sub PTV (1 | 15900) | ORGAN | BLADDER (15900) | | | | |
| | BODY (BODY) | | EXTERNAL | | | | | H |
| | CTV LNs L (Contro |)I) | сти | | | | | |
| | CTV LNs R (Contro | ol) | сти | | | = | | |
| | CTV_LN combined | I (CTV_Interm | сти | | | | | |
| | Femoral Head Lt (5 | 55012) | ORGAN | | | | | Here I |
| | Femoral Head Rt (| 55011) | ORGAN | | | | | 105. |
| - | Penile Bulb (19614 | | ORGAN | PenileBulb (19614) | | | | |
| Y: 0.00 c | Prostate (9600) | | сти | | | | | |
| Optimizati | PTV 77.4 (PTV_Hi | gh) | PTV | PTV (PTV_High) | ▼ 3240.0 cGy | | | |
| MLC | PTV_45 PELVIS (F | PTV_Intermed | PTV | | | | | |
| VMAT VMAT | PTV+1 (PRV) | | ORGAN | | | | | 1.7 0.00 1.7 0.00 |
| | | | | | | ÷ | | 5.0 0.00 |
| | | | | | | | Cancel | 5.0 0.00 5.0 0.00 |
| | | | | | | - Contraction of the second se | Lancor | 5.0 0.00 |

| Clinical Description Publishing Log | | | | | Edit Model and | Structures | | 7 | | N/A | | Ļ |
|---|-----------|--------|-----|----------|----------------|------------|---|---------------------|-------|---------|------|-----|
| Technical Description Training Log | | | | | | | 9 | | N/A | | | |
| | | | | | | | | 10 | | N/A | | |
| Model Structures and Objectives | | | | | | | | 11 | | N/A | | |
| - Target ID | Vol [%] | Dose | | Priority | gEUD a | | • | 15 | | N/A | | |
| Lower | 100.0 | 97.0 | % | 150 | | | | 16 | | N/A | | |
| Lower | 98.0 | 100.0 | % | 150 | | | | 23 | | N/A | | |
| BLADDER (15900 |)) | | | | | | | 24 | | N/A | | |
| Upper (fixed dose, generated vol.) | Generated | 95.0 | % | 80 |] | х | | ΡΤ | /: DV | 'H plot | | |
| Upper (fixed dose, generated vol.) | Generated | 50.0 | % | 80 |] | х | = | | | | | |
| Upper (fixed dose, generated vol.) | Generated | 25.0 | % | 30 | | | | | 100.0 | | | |
| Line (preferring target) | Generated | Genera | ted | Generate | i | | | | 80.0 | | | |
| Femur_L (24475 | 5) | | | | | | | (%) | | | | |
| Line (preferring target) | Generated | Genera | ted | Generate | 1 | х | | Relative Volume (%) | 60.0 | | | |
| Femur_R (24474 | 9 | | | | | | | ve Vo | 0 | | | |
| Line (preferring target) | Generated | Genera | ted | Generate | i | x | | Relati | 40.0 | | | |
| PenileBulb (19614 | Ð | | | | | | | | 20.0 | | | |
| Line (preferring target) | Generated | Genera | ted | Generate | 1 | x | Ţ | | | | | |
| Normal Tissue Objective | | | | | | | | | 0.0 | 0.0 | 10.0 | 20. |
| Smoothing Parameters (for IMRT) | | | | | | | | | | | 10.0 | 20. |

Conclusions

- Use of TG-263's standardized nomenclature has reduced variation across users at multiple facilities
- Efficiencies in the planning and plan documentation processes were realized when users employed customized templates based on TG-263 standardized nomenclature across multiple software systems
- Utilization and compliance with TG-263 templates using standardized nomenclature has been observed in all LCI clinics



Conclusions



- TG-263's standardized nomenclature recommendations can be incorporated into the tx planning process across a number of software platforms
- The medical physicist can serve as a leader or contributor to an effective implementation strategy incorporating varied practice stakeholders

Thanks to Levine Cancer Institute:

- Physicists
- Radiation Oncologists
- Dosimetrists
 - Robyn Walker, CMD
 - Holly Fletcher